Compliance on Mandatory Data Reporting in Registered Obstetrics Trials

Jake X. Checketts, M. Blake Evans, Abha H. Athale, Omar M. Jawhar, Micah R. Wright, Kristine Bryant, Matt Vassar

Research output: Contribution to journalArticle

Abstract

Background The Food and Drug Administration's (FDA's) Amendments Act established a legal mandate requiring registration of certain drug, device, and biologics trials in ClinicalTrials.gov prior to patient enrollment. One provision of the act requires investigators to report trial results in ClinicalTrials.gov within 1 year of completion. Preliminary evidence suggests that overall compliance rates are inadequate, and rates specific to obstetrics have not been investigated. Objective The purpose of this study was to examine the rate of compliance for mandatory reporting of results from obstetrics trials to ClinicalTrials.gov and to determine whether compliance rates were associated with funding type. Study Design We performed a registry-based study of clinical trials pertaining to obstetrics. ClinicalTrials.gov was cross-referenced with Drugs@FDA to determine which trials required mandatory reporting. We used obstetrics trials registered on ClinicalTrials.gov with at least 1 US site. Phase 0, Phase 1, and trials not reporting a phase were excluded. Furthermore, only trials of interventions approved by the FDA were retained. Results Our search returned 973 trials, of which 325 (33.4%) were screened for eligibility. Of the 325 completed trials, 74 (22.8% or 7.6% of the total) met all inclusion criteria and were evaluated for compliance. Thirty-seven of these trials (50%) did not list results, whereas the remaining 37 trials (50%) contained results on ClinicalTrials.gov. Trials funded by the National Institutes of Health (87.5%; 7/8) and industry (80%; 12/15) had higher rates of compliance than trials funded by other (43.9%; 18/41) or unspecified (0%; 0/10) sources. Conclusion Half of all applicable obstetrics trials did not report results. Furthermore, rates of compliance appeared to vary by funding source, with trials funded by the National Institutes of Health or industry appearing to have a higher rate of compliance to mandatory data reporting. Greater awareness of federal regulations is needed, and changes should be implemented to increase reporting.

Original languageEnglish
Pages (from-to)1192-1196
Number of pages5
JournalAmerican Journal of Perinatology
Volume35
Issue number12
DOIs
StatePublished - 25 Apr 2018

Fingerprint

Mandatory Reporting
Compliance
Obstetrics
Research Design
United States Food and Drug Administration
National Institutes of Health (U.S.)
Industry
Biological Products
Pharmaceutical Preparations
Registries
Research Personnel
Clinical Trials
Equipment and Supplies

Keywords

  • ClinicalTrials.gov
  • antenatal
  • clinical trials
  • data reporting
  • fetal
  • intrapartum
  • obstetrics
  • postpartum
  • pregnancy
  • prenatal

Cite this

Checketts, Jake X. ; Evans, M. Blake ; Athale, Abha H. ; Jawhar, Omar M. ; Wright, Micah R. ; Bryant, Kristine ; Vassar, Matt. / Compliance on Mandatory Data Reporting in Registered Obstetrics Trials. In: American Journal of Perinatology. 2018 ; Vol. 35, No. 12. pp. 1192-1196.
@article{85347069c9334802969fe4da097ff3f5,
title = "Compliance on Mandatory Data Reporting in Registered Obstetrics Trials",
abstract = "Background The Food and Drug Administration's (FDA's) Amendments Act established a legal mandate requiring registration of certain drug, device, and biologics trials in ClinicalTrials.gov prior to patient enrollment. One provision of the act requires investigators to report trial results in ClinicalTrials.gov within 1 year of completion. Preliminary evidence suggests that overall compliance rates are inadequate, and rates specific to obstetrics have not been investigated. Objective The purpose of this study was to examine the rate of compliance for mandatory reporting of results from obstetrics trials to ClinicalTrials.gov and to determine whether compliance rates were associated with funding type. Study Design We performed a registry-based study of clinical trials pertaining to obstetrics. ClinicalTrials.gov was cross-referenced with Drugs@FDA to determine which trials required mandatory reporting. We used obstetrics trials registered on ClinicalTrials.gov with at least 1 US site. Phase 0, Phase 1, and trials not reporting a phase were excluded. Furthermore, only trials of interventions approved by the FDA were retained. Results Our search returned 973 trials, of which 325 (33.4{\%}) were screened for eligibility. Of the 325 completed trials, 74 (22.8{\%} or 7.6{\%} of the total) met all inclusion criteria and were evaluated for compliance. Thirty-seven of these trials (50{\%}) did not list results, whereas the remaining 37 trials (50{\%}) contained results on ClinicalTrials.gov. Trials funded by the National Institutes of Health (87.5{\%}; 7/8) and industry (80{\%}; 12/15) had higher rates of compliance than trials funded by other (43.9{\%}; 18/41) or unspecified (0{\%}; 0/10) sources. Conclusion Half of all applicable obstetrics trials did not report results. Furthermore, rates of compliance appeared to vary by funding source, with trials funded by the National Institutes of Health or industry appearing to have a higher rate of compliance to mandatory data reporting. Greater awareness of federal regulations is needed, and changes should be implemented to increase reporting.",
keywords = "ClinicalTrials.gov, antenatal, clinical trials, data reporting, fetal, intrapartum, obstetrics, postpartum, pregnancy, prenatal",
author = "Checketts, {Jake X.} and Evans, {M. Blake} and Athale, {Abha H.} and Jawhar, {Omar M.} and Wright, {Micah R.} and Kristine Bryant and Matt Vassar",
year = "2018",
month = "4",
day = "25",
doi = "10.1055/s-0038-1642620",
language = "English",
volume = "35",
pages = "1192--1196",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "12",

}

Compliance on Mandatory Data Reporting in Registered Obstetrics Trials. / Checketts, Jake X.; Evans, M. Blake; Athale, Abha H.; Jawhar, Omar M.; Wright, Micah R.; Bryant, Kristine; Vassar, Matt.

In: American Journal of Perinatology, Vol. 35, No. 12, 25.04.2018, p. 1192-1196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Compliance on Mandatory Data Reporting in Registered Obstetrics Trials

AU - Checketts, Jake X.

AU - Evans, M. Blake

AU - Athale, Abha H.

AU - Jawhar, Omar M.

AU - Wright, Micah R.

AU - Bryant, Kristine

AU - Vassar, Matt

PY - 2018/4/25

Y1 - 2018/4/25

N2 - Background The Food and Drug Administration's (FDA's) Amendments Act established a legal mandate requiring registration of certain drug, device, and biologics trials in ClinicalTrials.gov prior to patient enrollment. One provision of the act requires investigators to report trial results in ClinicalTrials.gov within 1 year of completion. Preliminary evidence suggests that overall compliance rates are inadequate, and rates specific to obstetrics have not been investigated. Objective The purpose of this study was to examine the rate of compliance for mandatory reporting of results from obstetrics trials to ClinicalTrials.gov and to determine whether compliance rates were associated with funding type. Study Design We performed a registry-based study of clinical trials pertaining to obstetrics. ClinicalTrials.gov was cross-referenced with Drugs@FDA to determine which trials required mandatory reporting. We used obstetrics trials registered on ClinicalTrials.gov with at least 1 US site. Phase 0, Phase 1, and trials not reporting a phase were excluded. Furthermore, only trials of interventions approved by the FDA were retained. Results Our search returned 973 trials, of which 325 (33.4%) were screened for eligibility. Of the 325 completed trials, 74 (22.8% or 7.6% of the total) met all inclusion criteria and were evaluated for compliance. Thirty-seven of these trials (50%) did not list results, whereas the remaining 37 trials (50%) contained results on ClinicalTrials.gov. Trials funded by the National Institutes of Health (87.5%; 7/8) and industry (80%; 12/15) had higher rates of compliance than trials funded by other (43.9%; 18/41) or unspecified (0%; 0/10) sources. Conclusion Half of all applicable obstetrics trials did not report results. Furthermore, rates of compliance appeared to vary by funding source, with trials funded by the National Institutes of Health or industry appearing to have a higher rate of compliance to mandatory data reporting. Greater awareness of federal regulations is needed, and changes should be implemented to increase reporting.

AB - Background The Food and Drug Administration's (FDA's) Amendments Act established a legal mandate requiring registration of certain drug, device, and biologics trials in ClinicalTrials.gov prior to patient enrollment. One provision of the act requires investigators to report trial results in ClinicalTrials.gov within 1 year of completion. Preliminary evidence suggests that overall compliance rates are inadequate, and rates specific to obstetrics have not been investigated. Objective The purpose of this study was to examine the rate of compliance for mandatory reporting of results from obstetrics trials to ClinicalTrials.gov and to determine whether compliance rates were associated with funding type. Study Design We performed a registry-based study of clinical trials pertaining to obstetrics. ClinicalTrials.gov was cross-referenced with Drugs@FDA to determine which trials required mandatory reporting. We used obstetrics trials registered on ClinicalTrials.gov with at least 1 US site. Phase 0, Phase 1, and trials not reporting a phase were excluded. Furthermore, only trials of interventions approved by the FDA were retained. Results Our search returned 973 trials, of which 325 (33.4%) were screened for eligibility. Of the 325 completed trials, 74 (22.8% or 7.6% of the total) met all inclusion criteria and were evaluated for compliance. Thirty-seven of these trials (50%) did not list results, whereas the remaining 37 trials (50%) contained results on ClinicalTrials.gov. Trials funded by the National Institutes of Health (87.5%; 7/8) and industry (80%; 12/15) had higher rates of compliance than trials funded by other (43.9%; 18/41) or unspecified (0%; 0/10) sources. Conclusion Half of all applicable obstetrics trials did not report results. Furthermore, rates of compliance appeared to vary by funding source, with trials funded by the National Institutes of Health or industry appearing to have a higher rate of compliance to mandatory data reporting. Greater awareness of federal regulations is needed, and changes should be implemented to increase reporting.

KW - ClinicalTrials.gov

KW - antenatal

KW - clinical trials

KW - data reporting

KW - fetal

KW - intrapartum

KW - obstetrics

KW - postpartum

KW - pregnancy

KW - prenatal

UR - http://www.scopus.com/inward/record.url?scp=85046037933&partnerID=8YFLogxK

U2 - 10.1055/s-0038-1642620

DO - 10.1055/s-0038-1642620

M3 - Article

C2 - 29695018

AN - SCOPUS:85046037933

VL - 35

SP - 1192

EP - 1196

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 12

ER -